These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38692813)

  • 41. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
    Cagle PT; Sholl LM; Lindeman NI; Alsabeh R; Divaris DX; Foulis P; Lee G; Neal JW; Nowak JA; Yu PP;
    Arch Pathol Lab Med; 2014 Feb; 138(2):171-4. PubMed ID: 23808401
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
    Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
    Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
    Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).
    Nellesen D; Dea K; Guerin A; Culver KW; Mutebi A; Dalal A
    Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP37-SP42. PubMed ID: 29689141
    [No Abstract]   [Full Text] [Related]  

  • 46. [Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology].
    Savic S; Bihl MP; Bubendorf L
    Pathologe; 2012 Jul; 33(4):301-7. PubMed ID: 22711372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography (FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancer.
    Werner L; Keller FA; Bhure U; Roos JE; Tornquist K; Del Sol Pèrez-Lago M; Gautschi O; Strobel K
    BMC Med Imaging; 2017 Jul; 17(1):41. PubMed ID: 28693444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current concepts on the molecular pathology of non-small cell lung carcinoma.
    Fujimoto J; Wistuba II
    Semin Diagn Pathol; 2014 Jul; 31(4):306-13. PubMed ID: 25239274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Sampling and search for the EGFR mutation: what's taking, when and how to test?].
    Cadranel J; Giroux Leprieur E
    Rev Pneumol Clin; 2011 Jun; 67 Suppl 1():S9-14. PubMed ID: 21777768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
    Vanderlaan PA; Yamaguchi N; Folch E; Boucher DH; Kent MS; Gangadharan SP; Majid A; Goldstein MA; Huberman MS; Kocher ON; Costa DB
    Lung Cancer; 2014 Apr; 84(1):39-44. PubMed ID: 24513263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive testing in non-small cell lung carcinoma.
    Dundr P; Matěj R; Němejcová K; Bártů M; Stružinská I
    Klin Onkol; 2021; 34(Supplementum 1):29-34. PubMed ID: 34154327
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study.
    Fintelmann FJ; Martin NA; Tahir I; Quinn EM; Allen TC; Joseph L; Nikolic B; Lee C
    Respir Res; 2023 Jan; 24(1):17. PubMed ID: 36650544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
    Gridelli C; de Marinis F; Ardizzoni A; Novello S; Fontanini G; Cappuzzo F; Grossi F; Santo A; Cortinovis D; Favaretto A; Lorusso V; Galetta D; Siena S; Bettini A; Iurlaro M; Caprioli A;
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1783-93. PubMed ID: 24903964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adequacy of cytology and small biopsy samples obtained with rapid onsite evaluation (ROSE) for predictive biomarker testing in non-small cell lung cancer.
    Hendry S; Mamotte L; Mesbah Ardakani N; Leslie C; Tesfai Y; Grieu-Iacopetta F; Izaac K; Singh S; Ardakani R; Thomas M; Giardina T; Robinson C; Frost F; Amanuel B
    Pathology; 2023 Dec; 55(7):917-921. PubMed ID: 37805343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
    Planchard D; Remon J; Nowak F; Soria JC
    Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
    [No Abstract]   [Full Text] [Related]  

  • 57. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
    Pennell NA; Arcila ME; Gandara DR; West H
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():531-542. PubMed ID: 31099633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
    Navani N; Butler R; Ibrahimo S; Verma A; Evans M; Doherty GJ; Ahmed S
    Lung Cancer; 2022 Oct; 172():142-153. PubMed ID: 36099709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?
    Ganti AK
    Oncology (Williston Park); 2018 Jun; 32(6):276-80. PubMed ID: 29940057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.